Be the most trusted biotech company

Henlius and Abbott Entered into a Semi-Exclusive License Agreement of HANLIKANG and HANQUYOU in Brazil


Shanghai, China, May 24th, 2022 - Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. ("Abbott") for the commercialization of Henlius independently developed HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac®) in Brazil.

Abbott Operations Uruguay S.R.L. is a wholly owned subsidiary of Abbott Laboratories, listed on the New York Stock Exchange (stock code: ABT). Abbott will pay to the company an upfront fee of US$3.0 million upon execution of the Product License Agreement and not more than US$1.4 million in aggregate on certain regulatory milestone payments pursuant to the terms and conditions of the Product License Agreement. Entering into the Product License Agreement with Abbott will help the company to further expand the overseas market of the Licensed Products. Leveraging Abbott’s presence in the Territory will further strengthen the accessibility of the Licensed Products to meet the needs of patients in the Territory.


HANLIKANG (rituximab), a rituximab biosimilar independently developed by the Company, which was approved for commercialisation by National Medical Products Administration ("NMPA") in February 2019. Three indications of HANLIKANG approved are: (1) Non-Hodgkin’s lymphoma; (2) Chronic Lymphocytic Leukemia (CLL); and (3) Rheumatoid Arthritis (RA).


HANQUYOU (trastuzumab, trade name in Europe: Zercepac®) , a trastuzumab biosimilar independently developed by the Company, which was approved for commercialisation in all EU Member States, Iceland, Liechtenstein and Norway and Chinese Mainland by the European Commission (EC) and NMPA in July 2020 and August 2020, respectively. Three indications of HANQUYOU approved are: (1) HER2-positive early breast cancer; (2) HER2-positive metastatic breast cancer; and (3) HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. The sales promotion of HANQUYOU in Chinese Mainland is conducted by the Company’s inhouse commercialization team.